Departments of Psychiatry (J.N.H., P.Z., L.M.R., P.G., S.M.C., T.D.G.), Pharmacology (P.Z., T.D.G.), Physiology (P.Z.), Anatomy and Neurobiology (T.D.G), Epidemiology and Public Health, Division of Translational Toxicology (E.F.R.P.), Programs in Toxicology (J.N.H.) and Neuroscience (L.M.R.), and Veterans Affairs Maryland Health Care System, University of Maryland School of Medicine, Baltimore, Maryland (T.D.G.); Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Intramural Research Program, National Institutes of Health, Rockville, Maryland (P.J.M., C.J.T.); Biomedical Research Center, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, Maryland (R.M.); Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland (C.A.Z.).
Departments of Psychiatry (J.N.H., P.Z., L.M.R., P.G., S.M.C., T.D.G.), Pharmacology (P.Z., T.D.G.), Physiology (P.Z.), Anatomy and Neurobiology (T.D.G), Epidemiology and Public Health, Division of Translational Toxicology (E.F.R.P.), Programs in Toxicology (J.N.H.) and Neuroscience (L.M.R.), and Veterans Affairs Maryland Health Care System, University of Maryland School of Medicine, Baltimore, Maryland (T.D.G.); Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Intramural Research Program, National Institutes of Health, Rockville, Maryland (P.J.M., C.J.T.); Biomedical Research Center, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, Maryland (R.M.); Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland (C.A.Z.)
Pharmacol Rev. 2021 Apr;73(2):763-791. doi: 10.1124/pharmrev.120.000149.
Hydroxynorketamines (HNKs) are formed in vivo after (,)-ketamine (ketamine) administration. The 12 HNK stereoisomers are distinguished by the position of cyclohexyl ring hydroxylation (at the 4, 5, or 6 position) and their unique stereochemistry at two stereocenters. Although HNKs were initially classified as inactive metabolites because of their lack of anesthetic effects, more recent studies have begun to reveal their biologic activities. In particular, (,)- and ( )-HNK exert antidepressant-relevant behavioral and physiologic effects in preclinical models, which led to a rapid increase in studies seeking to clarify the mechanisms by which HNKs exert their pharmacological effects. To date, the majority of HNK research has focused on the actions of (,)-HNK because of its robust behavioral actions in tests of antidepressant effectiveness and its limited adverse effects. This review describes HNK pharmacokinetics and pharmacodynamics, as well as the putative cellular, molecular, and synaptic mechanisms thought to underlie their behavioral effects, both following their metabolism from ketamine and after direct administration in preclinical studies. Converging preclinical evidence indicates that HNKs modulate glutamatergic neurotransmission and downstream signaling pathways in several brain regions, including the hippocampus and prefrontal cortex. Effects on other neurotransmitter systems, as well as possible effects on neurotrophic and inflammatory processes, and energy metabolism, are also discussed. Additionally, the behavioral effects of HNKs and possible therapeutic applications are described, including the treatment of unipolar and bipolar depression, post-traumatic stress disorder, chronic pain, neuroinflammation, and other anti-inflammatory and analgesic uses. SIGNIFICANCE STATEMENT: Preclinical studies indicate that hydroxynorketamines (HNKs) exert antidepressant-relevant behavioral actions and may also have analgesic, anti-inflammatory, and other physiological effects that are relevant for the treatment of a variety of human diseases. This review details the pharmacokinetics and pharmacodynamics of the HNKs, as well as their behavioral actions, putative mechanisms of action, and potential therapeutic applications.
羟去甲氯胺酮(HNKs)在(-)-氯胺酮(氯胺酮)给药后在体内形成。12 种 HNK 立体异构体通过环己基环羟化的位置(在 4、5 或 6 位)和两个手性中心的独特立体化学结构来区分。尽管 HNKs 最初因其缺乏麻醉作用而被归类为无活性代谢物,但最近的研究开始揭示它们的生物学活性。特别是,(-)-和()-HNK 在临床前模型中表现出抗抑郁相关的行为和生理效应,这导致了大量研究的快速增加,旨在阐明 HNK 发挥其药理作用的机制。迄今为止,由于(-)-HNK 在抗抑郁有效性测试中的强大行为作用及其有限的不良反应,大多数 HNK 研究都集中在(-)-HNK 上。本文描述了 HNK 的药代动力学和药效学,以及假设的细胞、分子和突触机制,这些机制被认为是其行为效应的基础,既包括从氯胺酮代谢而来,也包括在临床前研究中直接给药后的行为效应。趋同的临床前证据表明,HNKs 调节几种脑区中的谷氨酸能神经传递和下游信号通路,包括海马体和前额叶皮层。还讨论了对其他神经递质系统的影响,以及对神经营养和炎症过程以及能量代谢的可能影响。此外,还描述了 HNKs 的行为效应和可能的治疗应用,包括治疗单相和双相抑郁症、创伤后应激障碍、慢性疼痛、神经炎症和其他抗炎和镇痛用途。意义声明:临床前研究表明,羟去甲氯胺酮(HNKs)发挥抗抑郁相关的行为作用,并且可能还具有镇痛、抗炎和其他与治疗各种人类疾病相关的生理作用。本文详细介绍了 HNKs 的药代动力学和药效学,以及它们的行为作用、可能的作用机制和潜在的治疗应用。